Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells.

摘要: Adjuvant chemotherapy has become the frequently adopted standard therapeutic approach for non-small cell lung cancer (NSCLC). However, development of multidrug resistance (MDR) is a major obstacle contributing to failure chemotherapy. This study aimed identify genes associated with MDR that predict tumor response in NSCLC. In present study, multidrug-resistant NSCLC sub-line, A549/MDR, was established from A549/DDP line and characterized. The index (RI) this subline calculated according IC50 A549/MDR relative parental cells. gene expression profiles were obtained using an oligonucleotide microarray (Agilent SureHyb chip). results validated by qRT-PCR selected analyzed vitro loss-of-function experiments. Gene profiling identified 921 differentially expressed (DEGs) selection criteria, which 541 upregulated 380 downregulated compared We found these DEGs are involved diverse biological processes, including ribonucleoprotein complex, drug metabolism, Hippo signaling pathway transcriptional misregulation. NOLC1, as one DEGs, confirmed be overexpressed cells its knockdown significantly enhanced sensitivity treatment. Furthermore, NOLC1 levels resistance-associated molecules (LRP MDR1) These findings provide new comprehensive profile Identification validation might promising strategy management patients.